Literature DB >> 17053872

Alois Alzheimer revisited: differences in origin of the disease carrying his name.

K Maurer1, S Hoyer.   

Abstract

Based on the means of his time, Alois Alzheimer supposed that the disease, later carrying his name, is a disease of older age, and that the pathomorphological structures he described are due to disturbances in brain metabolism. In this contribution, it is discussed which cellular metabolic abnormalities may be representative for age-related sporadic Alzheimer disease (SAD) the predominant form of SAD in contrast to the very rare hereditary early-onset form. In focus are disturbances in glucose/energy metabolism which involve the deficits in acetylcholine, cholesterol and UDP-N-acetylglucosamine beside ATP. Another leading abnormality is the defect in cell membrane composition. The interrelation between abnormal glucose/energy metabolism and membrane defect may be assumed to form the basis for the induction of both the perturbed metabolism of the amyloid precursor protein leading to increased formation of beta-amyloid and hyperphosphorylation of tau-protein destroying cell structures. Alois Alzheimer may have been so prescient to assume most of this 100 years ago.

Entities:  

Mesh:

Year:  2006        PMID: 17053872     DOI: 10.1007/s00702-006-0592-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  169 in total

Review 1.  Regulation of the Na+/K+-ATPase by insulin: why and how?

Authors:  G Sweeney; A Klip
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

2.  Failure to maintain glycolysis in anoxic nerve terminals.

Authors:  R A Kauppinen; D G Nicholls
Journal:  J Neurochem       Date:  1986-12       Impact factor: 5.372

Review 3.  Copernicus revisited: amyloid beta in Alzheimer's disease.

Authors:  J Joseph; B Shukitt-Hale; N A Denisova; A Martin; G Perry; M A Smith
Journal:  Neurobiol Aging       Date:  2001 Jan-Feb       Impact factor: 4.673

4.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

5.  Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains.

Authors:  Marie Molander-Melin; Kaj Blennow; Nenad Bogdanovic; Birgitta Dellheden; Jan-Eric Månsson; Pam Fredman
Journal:  J Neurochem       Date:  2005-01       Impact factor: 5.372

6.  Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis.

Authors:  S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

7.  Decreased tyrosine kinase activity of insulin receptor isolated from rat adipocytes rendered insulin-resistant by catecholamine treatment in vitro.

Authors:  H Häring; D Kirsch; B Obermaier; B Ermel; F Machicao
Journal:  Biochem J       Date:  1986-02-15       Impact factor: 3.857

8.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

Authors:  Christopher J Phiel; Christina A Wilson; Virginia M-Y Lee; Peter S Klein
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

Review 9.  The cholinergic pathology in Alzheimer's disease--discrepancies between clinical experience and pathophysiological findings.

Authors:  L Frölich
Journal:  J Neural Transm (Vienna)       Date:  2002-07       Impact factor: 3.575

10.  Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine.

Authors:  E R Peskind; D Wingerson; S Murray; M Pascualy; D J Dobie; P Le Corre; R Le Verge; R C Veith; M A Raskind
Journal:  Arch Gen Psychiatry       Date:  1995-09
View more
  9 in total

Review 1.  Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible?

Authors:  Ryan Naylor; Andrew F Hill; Kevin J Barnham
Journal:  Eur Biophys J       Date:  2007-12-07       Impact factor: 1.733

2.  Aging and neurogenesis, a lesion from Alzheimer's disease.

Authors:  Philippe Taupin
Journal:  Aging Dis       Date:  2010-04-28       Impact factor: 6.745

Review 3.  From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain.

Authors:  P Riederer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

4.  Long-term effects of corticosterone on behavior, oxidative and energy metabolism of parietotemporal cerebral cortex and hippocampus of rats: comparison to intracerebroventricular streptozotocin.

Authors:  Siegfried Hoyer; Heinrich Lannert
Journal:  J Neural Transm (Vienna)       Date:  2008-08-05       Impact factor: 3.575

5.  Cardiovascular dementia - a different perspective.

Authors:  Udhaya Kumari; Klaus Heese
Journal:  Open Biochem J       Date:  2010-03-26

6.  Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease.

Authors:  Verónica Berta Dorfman; Laura Pasquini; Miguel Riudavets; Juan José López-Costa; Andrés Villegas; Juan Carlos Troncoso; Francisco Lopera; Eduardo Miguel Castaño; Laura Morelli
Journal:  Neurobiol Aging       Date:  2008-11-18       Impact factor: 4.673

Review 7.  Glucose metabolism and AD: evidence for a potential diabetes type 3.

Authors:  Andrea González; Camila Calfío; Macarena Churruca; Ricardo B Maccioni
Journal:  Alzheimers Res Ther       Date:  2022-04-20       Impact factor: 8.823

Review 8.  Prediabetes and Alzheimer's Disease.

Authors:  V R Bitra; Deepthi Rapaka; Annapurna Akula
Journal:  Indian J Pharm Sci       Date:  2015 Sep-Oct       Impact factor: 0.975

Review 9.  The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia.

Authors:  Jaume Folch; Miren Ettcheto; Oriol Busquets; Elena Sánchez-López; Rubén D Castro-Torres; Ester Verdaguer; Patricia R Manzine; Saghar Rabiei Poor; María Luisa García; Jordi Olloquequi; Carlos Beas-Zarate; Carme Auladell; Antoni Camins
Journal:  Pharmaceuticals (Basel)       Date:  2018-01-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.